Company Announcements

19 November 2024

4basebio plc

(“4basebio” or the "Company")
 

Director’s Dealing

19 November 2024 – 4basebio PLC (AIM: 4BB) (“4basebio” or the “Company”), which develops and commercialises the large scale manufacture of synthetic DNA as well as nanoparticle delivery solutions, announces that it was informed by Heikki Lanckriet , CEO of the Company, that he transferred 46,500 ordinary shares in the Company from his SIPP into his personal account. The transfer was effected by the sale and repurchase of a total of 46,500 ordinary shares at a price of 1,325 pence each.

Following the transfer, there is no change to Mr Lanckriet’s beneficial holding and his interest in the Company remains at 1,103,288 ordinary shares, representing approximately 7.3 per cent. of the Company's issued share capital.

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014 as amended by regulation 11 of the market abuse (amendment) (EU Exit) regulations 2019/310.

Enquiries

        4basebio PLC
                                       +44 (0)1223 967 943
Dr. Heikki Lanckriet

Nominated Adviser

Cairn Financial Advisers LLP           +44 (0)20 7213 0880

Jo Turner / Sandy Jamieson / Ed Downes

Joint Corporate Broker

RBC Capital Markets                    +44 (0)20 7653 4000

Rupert Walford / Kathryn Deegan

Joint Corporate Broker

Cavendish Capital Markets Limited      +44 (0)20 7220 0500

Geoff Nash / Nigel Birks

Notes to Editors

About 4basebio

4basebio (AIM: 4BB) is an innovation driven life biotechnology company focused on accelerating the development of advanced therapy medicinal products (ATMPs) through its high-performance synthetic DNA products and non-viral, cell targeting nucleic acid delivery platform. The Company’s objective is to become a market leader in the manufacture and supply of high-quality synthetic DNA products for research, therapeutic and pharmacological use as well as development of target specific non-viral vectors for the efficient delivery of payloads in patients.

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No.
596/2014

1  Details of the person discharging managerial responsibilities/person
   closely associated

a. Name                   Dr Heikki Lanckriet

2  Reason for
   notification

a. Position/Status        CEO

b. Initial                Initial Notification
   notification/Amendment

3  Details of the issuer, emission allowance market participant, auction
   platform, auctioneer or auction monitor

a. Name                   4basebio plc

b. LEI                    213800E2DX9EAIUNCB30

   Details of the transaction(s): section to be repeated for (i) each type of
4  instrument; (ii) each type of transaction; (iii) each date; and (iv) each
   place where transactions have been conducted

   Description of the
   financial instrument,  Ordinary Shares
a. type of instrument
                          ISIN: GB00BMCLYF79
   Identification Code

   Nature of the          Transfer of ordinary shares between accounts, via a
b. transaction            sale and repurchase, with no resultant change to
                          beneficial holding

                           Price(s) per share Volume(s)
                           (p)

                           1,325p             93,000

   Aggregated information
d.                            --  93,000
       --  Volume             --  1,325 pence per share
       --  Price
e. Date of the            15/11/2024
   transaction

f. Place of the           London Stock Exchange, AIM
   transaction